Beyond Conventional Treatment: Herbal Medicine and Nutraceuticals as Complementary Therapies for COPD and Asthma.

Q3 Medicine
Open Respiratory Medicine Journal Pub Date : 2026-05-14 eCollection Date: 2026-01-01 DOI:10.2174/0118743064454037260510201039
Ghasaq Al Obaidi, Yusuf Saleeby, Joseph Varon, Natalie Durzynski, Jack Tuszynki, Matthew Halma
{"title":"Beyond Conventional Treatment: Herbal Medicine and Nutraceuticals as Complementary Therapies for COPD and Asthma.","authors":"Ghasaq Al Obaidi, Yusuf Saleeby, Joseph Varon, Natalie Durzynski, Jack Tuszynki, Matthew Halma","doi":"10.2174/0118743064454037260510201039","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) and asthma remain among the most prevalent respiratory disorders worldwide, characterized by chronic inflammation, oxidative stress, and impaired quality of life. Although there has been significant advancement in the pharmacologic therapies, complementary strategies that can potentially target the underlying mechanisms and complement the conventional treatment are growing in interest among numerous patients and providers. This narrative review used systematic search methods in PubMed, Google Scholar, and ScienceDirect to select herbal medicines and nutraceuticals that were studied for COPD and asthma, with a specific selection using objective pulmonary functionality parameters (FEV1, FVC, FEV1/FVC). Analysis of evidence identified multiple interventions with a clinically significant effect, such as <i>Astragalus membranaceus</i>, <i>Rhodiola rosea</i>, nanocurcumin, Bufei granule, and Wuqinxi breathing exercises, most of which have anti-inflammatory, antioxidant, and immunomodulatory effects. The other agents, including Withania somnifera, Maxingshigan decoction, and L-carnitine, exhibited significant but inconsistent efficacy, whereas compounds like N-acetylcysteine, resveratrol, and cannabis had little effect. Mechanistic research indicates NF-kB, MAPK, Nrf2, and cytokine signaling pathways as typical therapeutic targets. Despite the limitations of methodological heterogeneity, the results indicate the judicious use of the choice of herbal and nutraceutical interventions in comprehensive respiratory care. Such supportive interventions can be patient-centered, enhance medication compliance, and offer an added effect in combination with evidence-based pharmacologic therapies. The quality of therapeutic application of the drug needs to be established through further high-quality therapeutic trials in order to determine the safety, dosing, and long-term outcomes.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"20 ","pages":"e18743064454037"},"PeriodicalIF":0.0000,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458475/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Respiratory Medicine Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118743064454037260510201039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic obstructive pulmonary disease (COPD) and asthma remain among the most prevalent respiratory disorders worldwide, characterized by chronic inflammation, oxidative stress, and impaired quality of life. Although there has been significant advancement in the pharmacologic therapies, complementary strategies that can potentially target the underlying mechanisms and complement the conventional treatment are growing in interest among numerous patients and providers. This narrative review used systematic search methods in PubMed, Google Scholar, and ScienceDirect to select herbal medicines and nutraceuticals that were studied for COPD and asthma, with a specific selection using objective pulmonary functionality parameters (FEV1, FVC, FEV1/FVC). Analysis of evidence identified multiple interventions with a clinically significant effect, such as Astragalus membranaceus, Rhodiola rosea, nanocurcumin, Bufei granule, and Wuqinxi breathing exercises, most of which have anti-inflammatory, antioxidant, and immunomodulatory effects. The other agents, including Withania somnifera, Maxingshigan decoction, and L-carnitine, exhibited significant but inconsistent efficacy, whereas compounds like N-acetylcysteine, resveratrol, and cannabis had little effect. Mechanistic research indicates NF-kB, MAPK, Nrf2, and cytokine signaling pathways as typical therapeutic targets. Despite the limitations of methodological heterogeneity, the results indicate the judicious use of the choice of herbal and nutraceutical interventions in comprehensive respiratory care. Such supportive interventions can be patient-centered, enhance medication compliance, and offer an added effect in combination with evidence-based pharmacologic therapies. The quality of therapeutic application of the drug needs to be established through further high-quality therapeutic trials in order to determine the safety, dosing, and long-term outcomes.

超越传统治疗:草药和营养品作为慢性阻塞性肺病和哮喘的补充疗法。
慢性阻塞性肺疾病(COPD)和哮喘仍然是世界上最普遍的呼吸系统疾病,其特征是慢性炎症、氧化应激和生活质量受损。尽管在药物治疗方面已经取得了重大进展,但许多患者和提供者越来越感兴趣的是能够潜在地针对潜在机制并补充传统治疗的补充策略。本叙述性综述使用PubMed、b谷歌Scholar和ScienceDirect的系统搜索方法,选择用于COPD和哮喘研究的草药和营养品,并使用客观肺功能参数(FEV1、FVC、FEV1/FVC)进行具体选择。证据分析发现,黄芪、红景天、纳米姜黄素、补肺颗粒、五芩西呼吸练习等多种干预措施均具有临床显著效果,多数具有抗炎、抗氧化和免疫调节作用。其他药物,包括Withania somnifera, Maxingshigan汤和左旋肉碱,表现出显著但不一致的效果,而n -乙酰半胱氨酸,白藜芦醇和大麻等化合物几乎没有效果。机制研究表明NF-kB、MAPK、Nrf2和细胞因子信号通路是典型的治疗靶点。尽管方法学异质性存在局限性,但结果表明,在综合呼吸保健中,草药和营养保健干预措施的选择是明智的。这种支持性干预可以以患者为中心,增强药物依从性,并与循证药物治疗相结合,提供额外的效果。药物的治疗应用质量需要通过进一步的高质量治疗试验来确定,以确定安全性、剂量和长期结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Open Respiratory Medicine Journal
Open Respiratory Medicine Journal Medicine-Pulmonary and Respiratory Medicine
CiteScore
1.70
自引率
0.00%
发文量
17
期刊介绍: The Open Respiratory Medicine Journal is an Open Access online journal, which publishes research articles, reviews/mini-reviews, letters and guest edited single topic issues in all important areas of experimental and clinical research in respiratory medicine. Topics covered include: -COPD- Occupational disorders, and the role of allergens and pollutants- Asthma- Allergy- Non-invasive ventilation- Therapeutic intervention- Lung cancer- Lung infections respiratory diseases- Therapeutic interventions- Adult and paediatric medicine- Cell biology. The Open Respiratory Medicine Journal, a peer reviewed journal, is an important and reliable source of current information on important recent developments in the field. The emphasis will be on publishing quality articles rapidly and making them freely available worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书